Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Neoplasia

• DOI: 10.1053/j.gastro.2024.02.033
• Publication Date: 2024-03-04T07:15:40Z
• Authors: Sanne.N. van Munster; Eva P.D. Verheij; Özge Ozdemir; Esther Toes-Zoute...; Iris Lansdorp-Vog...; Esther A. Nieuwen...; Cary C. Cotton; Bas L.A.M. Weusten; Lorenza Alvarez H...; Alaa Alkhalaf; B. Ed Schenk; Erik J. Schoon; Wouter L. Curvers; Arjun D. Koch; Pieter-Jan F. de ...; Thjon J. Tang; Wouter B. Nagengast; Jessie Westerhof; Martin H.M.G. Houben; Nicholas J. Shaheen; Jacques J.G.H.M. ...; Roos E. Pouw
• Keywords: Male; Time Factors; Esophageal Cancer; Hepatology; Esophageal Neoplasms; Incidence; Gastroenterology; Comorbidity; Middle Aged; Adenocarcinoma; Risk Assessment; Barrett Esophagus; Treatment Outcome; SDG 3 - Good Health and Well-being; Risk Factors; Cause of Death; Humans; Female; Endoscopic Treatment; Registries; Esophagoscopy; Mortality; Charlson Comorbidity Index; Netherlands; Aged

Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett's neoplasia do not consider the risk of mortality from causes other than esophageal adenocarcinoma (EAC). We aimed to evaluate this risk during long-term FU, and to assess whether the Charlson Comorbidity Index (CCI) can predict mortality.We included all patients with successful EET from the nationwide Barrett registry in the Netherlands. Data were merged with National Statistics for accurate mortality data. We evaluated annual mortality rates (AMRs, per 1000 person-years) and standardized mortality ratio for other-cause mortality. Performance of the CCI was evaluated by discrimination and calibration.We included 1154 patients with a mean age of 64 years (±9). During median 59 months (p25-p75 37-91; total 6375 person-years), 154 patients (13%) died from other causes than EAC (AMR, 24.1; 95% CI, 20.5-28.2), most commonly non-EAC cancers (n = 58), cardiovascular (n = 31), or pulmonary diseases (n = 26). Four patients died from recurrent EAC (AMR, 0.5; 95% CI, 0.1-1.4). Compared with the general Dutch population, mortality was significantly increased for patients in the lowest 3 age quartiles (ie, age <71 years). Validation of CCI in our population showed good discrimination (Concordance statistic, 0.78; 95% CI, 0.72-0.84) and fair calibration.The other-cause mortality risk after successful EET was more than 40 times higher (48; 95% CI, 15-99) than the risk of EAC-related mortality. Our findings reveal that younger post-EET patients exhibit a significantly reduced life expectancy when compared with the general population. Furthermore, they emphasize the strong predictive ability of CCI for long-term mortality after EET. This straightforward scoring system can inform decisions regarding personalized FU, including appropriate cessation timing. (NL7039).